The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer
Official Title: Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer
Study ID: NCT01827943
Brief Summary: In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.
Detailed Description: In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. This study will also search for genes involved in the response to treatment.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU de Bordeaux, Bordeaux, , France
Centre François Baclesse, Caen, , France
Centre Jean Perrin, Clermont Ferrand, , France
CHU Henri Mondor, Créteil, , France
Centre Léon Bérard, Lyon, , France
Hôpital d'instruction des armées du Val-de-Grâce, Paris, , France
CHU de Rouen, Rouen, , France
Institut Claudius Regaud, Toulouse, , France
CHU de Toulouse, Toulouse, , France
Name: Nadine HOUEDE, MD
Affiliation: Institut Bergonié
Role: STUDY_CHAIR